Trial Profile
Randomized Phase II/III-Study on All-Trans Retinoic Acid in Combination With Induction and Consolidation Therapy as Well as Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 May 2021
Price :
$35
*
At a glance
- Drugs Tretinoin (Primary) ; Cytarabine; Etoposide; Idarubicin; Pegfilgrastim
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 17 Feb 2021 Results (n=75) of RATIFY, AMLSG 16-10, AMLSG 07-04 and AMLSG 11-08 trials assessing clonal evolution of FLT3-ITD positive AML in patients with relapsed and refractory disease who were treated with intensive chemotherapy in combination with the multi-kinase inhibitor midostaurin, published in the Blood.
- 06 Dec 2016 Results of analysis comparing condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim using data from this trial presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Results assessing minimal residual disease monitoring in Acute Myeloid Leukemia study group (AML HD93, NCT00146120, NCT00151255, NCT00151242, NCT00850382 and NCT02013648 trials) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology